Thiotepa


Alkylating agent acting upon synthesis of desoxyri-bonucleoproteins. Used in the treatment of ovarian, breast cancer and bladder tumors (intravesical instillation).
 
Incidence
3% of intravesical infusions.
 
Risk factors
Bladder instillation.
 
Clinical manifestations
General: fever.
 
Cutaneous: pruritus, urticaria. angioedema.
 
Diagnostic methods
No in vivo or in vitro method is currently available for diagnosis.
 
Management
Avoid use. 

References

  1. Lee M, Sharifi R, "Generalized hypersensitivity reaction to intravesical thiotepa and doxorubicin", J. Urol., 1987; 138 (1): 143–4.
  2. Hu K.N, Kim A, Khan A.S, Soroff H, Gonder M, "Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor", Cancer, 1985; 55 (8): 1654-8

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.